Henry Schein to acquire majority stake in France’s Biotech Dental Group

Search Dental Tribune

Henry Schein to acquire majority stake in France’s Biotech Dental Group

E-Newsletter

The latest news in dentistry free of charge.

  • This field is for validation purposes and should be left unchanged.
Henry Schein has agreed to acquire a majority stake in Biotech Dental Group, one of France’s leading dental manufacturers. (Image: Krakenimages.com/Shutterstock)
Dental Tribune International

Dental Tribune International

Tue. 27 December 2022

save

NEW YORK, US: Global dental distributor Henry Schein will purchase a majority share in Biotech Dental with the aim of expanding its offering in some of dentistry’s fastest-moving product and service categories. The deal, which is subject to regulatory approval, would boost the US dental giant’s access to clinical software, dental implants and a range of oral surgery and orthodontic products.

Biotech Dental is a rapidly growing provider of clinical software and oral surgery and orthodontic products and is based in Salon-de-Provence in France. The two companies have entered into a definitive sales agreement that means that Henry Schein acquires majority ownership of Biotech Dental and the current majority owner Upperside Capital Partners Group controls the remaining minority share. The financial terms of the sales agreement were not disclosed.

Henry Schein said in a statement that the two companies would work together to bring Biotech Dental products to more dentists in more parts of the world. The French company’s portfolio includes software products and services, dental prostheses, clear aligners, dental implants, regenerative solutions and biomaterials. Some of its portfolio highlights are the Nemotec suite of planning and diagnostic software, a range of dental implant and custom abutment brands and the Smilers clear aligner system. Biotech Dental recently launched LaGalaxy, an open software platform where users can perform both clinical and administrative tasks.

“Henry Schein and Biotech Dental are committed to offering customers best-in-class, user-friendly, customer-centric solutions based on open architecture that help improve patient outcomes,” said Stanley M. Bergman, chairman of the board and CEO at Henry Schein, in the statement, adding that the company would incorporate Biotech’s Nemotec software as part of its offering and integrate its software solutions with existing practice management software. Bergman commented: “Biotech Dental has excelled in several of the most exciting and fastest-growing segments of the dental market, including implants and aligners. With our combined resources, we will introduce customers to state-of-the-art technology.”

Philippe Veran, co-founder and president of Biotech Dental, would continue to lead Biotech Dental’s operations after the acquisition. He commented: “For the past 35 years, the growth of our business has been rooted in our rich French heritage. This will remain as we continue to manufacture our products in France while bringing innovation and new technologies to the global dental community. Together, with Henry Schein, we look forward to helping our customers enhance their surgical skills, achieve better outcomes for their patients, and maximise business success.”

Henry Schein celebrated its 90th anniversary this year, looking back on a prodigious journey from its founding as a storefront pharmacy in Queens in New York City to a global dental and healthcare supplier. It has acquired at least 46 companies in diverse industries. They include dental, healthcare and veterinary distributors as well as software and laboratory businesses. In 2022, Henry Schein took two dental distributors under its wing—Condor Dental Research, which operates in Switzerland, and Midway Dental Supply, a dental distribution service operating in the Midwestern US.

Leave a Reply

Your email address will not be published. Required fields are marked *

advertisement
advertisement